Laninamivir (TFA)
Laninamivir TFA (R 125489 TFA) is an antiviral compound with inhibitory and prophylactic activity against influenza A and B viruses. Laninamivir TFA is a long-acting neuraminidase inhibitor administered by nasal inhalation. Laninamivir TFA has shown good safety and efficacy in the inhibition of influenza viruses[1].
Product Specifications
CAS Number
[203120-18-7]
Product Name Alternative
R 125489 (TFA)
UNSPSC
12352005
Target
Influenza Virus
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/laninamivir-tfa.html
Solubility
10 mM in DMSO
Smiles
OC[C@@H](O)[C@H]([C@@]1([H])[C@@H]([C@H](C=C(C(O)=O)O1)NC(N)=N)NC(C)=O)OC.OC(C(F)(F)F)=O
Molecular Formula
C15H23F3N4O9
Molecular Weight
460.36
References & Citations
[1]Vavricka CJ, et al. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog. 2011 Oct;7 (10) :e1002249.|[2]Antiviral Drugs in Influenza
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15309515 1 Vial
Lentiviral human VDAC2 shRNA (UAS) - Lentiviral human VDAC2 shRNA (UAS, GFP) (25)
Ask
View Details 123844-ML405 100 µL
BAZ1B (WBSC10, WBSCR10, WBSCR9, WSTF, Tyrosine-protein Kinase BAZ1B, Bromodomain Adjacent to Zinc Finger Domain Protein 1B, Williams Syndrome Transcription Factor, Williams-Beuren Syndrome Chromosomal Region 10 Protein, Williams-Beuren Syndrome Chromosomal Region 9 Protein, hWALp2) (MaxLight 405) discontinued
Ask
View Details 